Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology81
Targeted Therapy & Precision Oncology98
Cell & Gene Therapy for Cancer36
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $1.0t | $1390.19 | 0.0% | 3.0K |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.6t | $277.00 | 0.0% | 2.8K |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $464.4b | $296.25 | 0.0% | 976 |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $356.0b | $148.48 | 0.0% | 6.3K |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $243.3b | $180.57 | 0.0% | 14.5K |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $217.9b | $472.98 | 0.0% | 1.6K |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $179.5b | $170.13 | 0.0% | 1.0K |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $124.9b | $62.52 | 0.0% | 1.4K |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $75.9b | $221.06 | 0.0% | 18.2K |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $75.7b | $829.03 | 0.0% | 187 |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $59.1b | $441.15 | 0.0% | 128 |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $44.3b | $188.06 | 0.0% | 59 |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $25.5b | $65.84 | 0.0% | 119 |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $23.9b | $184.97 | 0.0% | 2 |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $23.4b | $115.93 | 0.0% | 1.8K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $15.3b | $207.79 | 0.0% | N/A |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $14.5b | $62.97 | 0.0% | 106 |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $12.6b | $85.59 | 0.0% | N/A |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $12.5b | $129.49 | 0.0% | 100 |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $10.9b | $8.63 | 0.0% | 714 |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $9.8b | $123.96 | 0.0% | N/A |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $8.0b | $36.12 | 0.0% | 188 |
 ACLX | Arcellx, Inc. Common Stock | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $6.7b | $115.06 | -0.0% | 16.1M |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $6.5b | $100.11 | 0.0% | N/A |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $6.4b | $9.27 | 0.0% | 21.4K |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $6.4b | $155.99 | 0.0% | 95 |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $6.0b | $62.08 | 0.0% | N/A |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.4b | $31.83 | 0.0% | N/A |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.2b | $14.80 | 0.0% | N/A |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $5.0b | $114.66 | 0.0% | N/A |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $4.5b | $27.77 | 0.0% | N/A |
 ABCL | AbCellera Biologics Inc. Common Shares | Radiopharmaceuticals & ADCs | $4.5b | $12.59 | 0.0% | 7.0K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.2b | $18.88 | 0.0% | 2.0K |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $3.9b | $22.59 | 0.0% | N/A |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $3.7b | $51.95 | 0.0% | N/A |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.6b | $34.15 | 0.0% | 9 |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.5b | $69.33 | 0.0% | N/A |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.4b | $45.08 | 0.0% | N/A |
 PBLS | Parabilis Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.2b | $28.20 | 0.0% | N/A |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $3.1b | $18.79 | 0.0% | N/A |
 PGEN | Precigen, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $3.1b | $6.60 | 0.0% | 3 |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $2.4b | $27.13 | 0.0% | 8 |
 IMNM | Immunome, Inc. | Targeted Therapy & Precision OncologyRadiopharmaceuticals & ADCs | $2.4b | $18.29 | 0.0% | N/A |
 NEO | NeoGenomics, Inc. | Cancer Diagnostics & Biomarkers | $2.4b | $17.95 | 0.0% | N/A |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.4b | $10.08 | 0.0% | 3.8K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 URGN | UroGen Pharma Ltd. Ordinary Shares | Targeted Therapy & Precision Oncology | $2.0b | $33.52 | 0.0% | 17 |
 BHVN | Biohaven Ltd. | Targeted Therapy & Precision Oncology | $1.9b | $15.82 | 0.0% | 74 |
 VIR | Vir Biotechnology, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.9b | $11.82 | 0.0% | 2 |
 XNCR | Xencor, Inc. | Immunotherapy & Immuno-Oncology | $1.8b | $29.38 | 0.0% | 50 |